JP2022520832A5 - - Google Patents
Info
- Publication number
- JP2022520832A5 JP2022520832A5 JP2021547546A JP2021547546A JP2022520832A5 JP 2022520832 A5 JP2022520832 A5 JP 2022520832A5 JP 2021547546 A JP2021547546 A JP 2021547546A JP 2021547546 A JP2021547546 A JP 2021547546A JP 2022520832 A5 JP2022520832 A5 JP 2022520832A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- approximately
- corneal
- subject
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024177283A JP2025004186A (ja) | 2019-02-15 | 2024-10-09 | 眼表面疼痛を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806682P | 2019-02-15 | 2019-02-15 | |
| US62/806,682 | 2019-02-15 | ||
| PCT/IB2020/051210 WO2020165838A1 (en) | 2019-02-15 | 2020-02-13 | Methods for treating ocular surface pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177283A Division JP2025004186A (ja) | 2019-02-15 | 2024-10-09 | 眼表面疼痛を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520832A JP2022520832A (ja) | 2022-04-01 |
| JP2022520832A5 true JP2022520832A5 (enExample) | 2023-02-21 |
| JP7571037B2 JP7571037B2 (ja) | 2024-10-22 |
Family
ID=69740423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547546A Active JP7571037B2 (ja) | 2019-02-15 | 2020-02-13 | 眼表面疼痛を治療する方法 |
| JP2024177283A Pending JP2025004186A (ja) | 2019-02-15 | 2024-10-09 | 眼表面疼痛を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177283A Pending JP2025004186A (ja) | 2019-02-15 | 2024-10-09 | 眼表面疼痛を治療する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20200261456A1 (enExample) |
| EP (1) | EP3923909A1 (enExample) |
| JP (2) | JP7571037B2 (enExample) |
| KR (1) | KR20210129677A (enExample) |
| CN (1) | CN113453686B (enExample) |
| AU (2) | AU2020222348B2 (enExample) |
| BR (1) | BR112021015998A2 (enExample) |
| CA (1) | CA3130038A1 (enExample) |
| CL (1) | CL2021002152A1 (enExample) |
| IL (1) | IL284629A (enExample) |
| JO (1) | JOP20210217A1 (enExample) |
| MX (2) | MX2021009702A (enExample) |
| PH (1) | PH12021551968A1 (enExample) |
| SG (1) | SG11202107260VA (enExample) |
| TW (2) | TW202515576A (enExample) |
| WO (1) | WO2020165838A1 (enExample) |
| ZA (1) | ZA202104593B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| WO2022029656A1 (en) * | 2020-08-06 | 2022-02-10 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| CN119184616A (zh) * | 2024-09-03 | 2024-12-27 | 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) | 一种疼痛等级的测评方法及其评估系统 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| GB0412769D0 (en) * | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| BRPI0620264A2 (pt) | 2005-12-22 | 2011-11-08 | Prolexys Pharmaceuticals Inc | quinazolonas aril-substituìdas e sua utilização |
| TW200738232A (en) | 2006-01-31 | 2007-10-16 | Alcon Mfg Ltd | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| KR20100039410A (ko) | 2007-07-18 | 2010-04-15 | 노파르티스 아게 | Ｖｒ－１ 길항제 및 ｃｏｘ－２ 억제제의 상승적 조합물 |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| US8163901B2 (en) | 2008-01-09 | 2012-04-24 | Evotec Ag | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2009090548A2 (en) | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| WO2009149239A1 (en) | 2008-06-04 | 2009-12-10 | Children's Medical Center Corporation | Methods of modulating angiogenesis via trpv4 |
| WO2010023512A1 (en) | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2316420B1 (en) | 2009-10-22 | 2014-02-26 | Consorzio Universitario Unifarm | Topical ophthalmic composition to reduce pain |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| CN102875480A (zh) | 2012-04-23 | 2013-01-16 | 中国药科大学 | 喹唑啉酮类血管抑制剂、其制备方法及其医药用途 |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| US9827225B2 (en) | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| JP2019532054A (ja) | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| RU2019110821A (ru) | 2016-09-20 | 2020-10-22 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Антагонисты trpv4 |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| EP4431497A1 (en) | 2019-02-15 | 2024-09-18 | Bausch + Lomb Ireland Limited | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
-
2020
- 2020-02-13 KR KR1020217028994A patent/KR20210129677A/ko active Pending
- 2020-02-13 US US16/789,963 patent/US20200261456A1/en not_active Abandoned
- 2020-02-13 WO PCT/IB2020/051210 patent/WO2020165838A1/en not_active Ceased
- 2020-02-13 MX MX2021009702A patent/MX2021009702A/es unknown
- 2020-02-13 AU AU2020222348A patent/AU2020222348B2/en active Active
- 2020-02-13 JP JP2021547546A patent/JP7571037B2/ja active Active
- 2020-02-13 EP EP20708629.9A patent/EP3923909A1/en active Pending
- 2020-02-13 TW TW113123791A patent/TW202515576A/zh unknown
- 2020-02-13 TW TW109104537A patent/TWI878266B/zh active
- 2020-02-13 BR BR112021015998-3A patent/BR112021015998A2/pt unknown
- 2020-02-13 CN CN202080013685.7A patent/CN113453686B/zh active Active
- 2020-02-13 PH PH1/2021/551968A patent/PH12021551968A1/en unknown
- 2020-02-13 CA CA3130038A patent/CA3130038A1/en active Pending
- 2020-02-13 SG SG11202107260VA patent/SG11202107260VA/en unknown
-
2021
- 2021-04-08 US US17/225,290 patent/US11234982B2/en active Active
- 2021-07-01 ZA ZA2021/04593A patent/ZA202104593B/en unknown
- 2021-07-05 IL IL284629A patent/IL284629A/en unknown
- 2021-08-12 MX MX2025000353A patent/MX2025000353A/es unknown
- 2021-08-12 JO JOP/2021/0217A patent/JOP20210217A1/ar unknown
- 2021-08-13 CL CL2021002152A patent/CL2021002152A1/es unknown
-
2022
- 2022-03-08 US US17/653,982 patent/US20220193078A1/en not_active Abandoned
-
2023
- 2023-06-14 AU AU2023203716A patent/AU2023203716B2/en active Active
-
2024
- 2024-03-06 US US18/597,497 patent/US20240342174A1/en active Pending
- 2024-10-09 JP JP2024177283A patent/JP2025004186A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240210736A1 (en) | Mouse myopia-induced model and endoplasmic reticulum stress suppressant for preventing and suppressing myopia | |
| US10617735B2 (en) | Methods and compositions for preserving retinal ganglion cells | |
| RU2632107C2 (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| CN108135737A (zh) | 用于治疗翼状胬肉的组合物和方法 | |
| JP7474706B2 (ja) | ４－フェニル酪酸を含有する老視の治療または予防剤 | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| JP2022520832A5 (enExample) | ||
| CN110114066B (zh) | 含沙丁胺醇的眼科药物 | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| JP2024506384A (ja) | ロフルミラストの眼科的送達方法 | |
| US20240261273A1 (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
| JP7016880B2 (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| US12599609B2 (en) | Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis | |
| CN115052595B (zh) | 用于治疗神经学疾病或病症的新型治疗方法 | |
| US20220062255A1 (en) | Treatment of neurodegenerative eye disease using pridopidine | |
| TW201838629A (zh) | 用於預防近視、治療近視及／或預防近視增長之包含蕪地銨作爲活性成分的藥劑 | |
| CN115884782A (zh) | 新型干眼症治疗用药物组合物 | |
| JP4966019B2 (ja) | 慢性移植片対宿主症におけるドライアイの予防および治療剤 | |
| JP7197112B2 (ja) | 水泡性角膜症治療用医薬組成物 | |
| RU2846642C1 (ru) | Способ лечения передних увеитов собак средней степени тяжести | |
| US20260048028A1 (en) | Methods of Use for Disulfiram and Metabolites Thereof | |
| US20250170143A1 (en) | Methods of treating ocular fibrotic pathologies | |
| JP6850730B2 (ja) | 緑内障予防治療剤 | |
| Rewri et al. | Topiramate-induced secondary angle closure | |
| CN107106572A (zh) | 角膜上皮障碍治疗剂 |